[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015006062A - Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma. - Google Patents

Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma.

Info

Publication number
MX2015006062A
MX2015006062A MX2015006062A MX2015006062A MX2015006062A MX 2015006062 A MX2015006062 A MX 2015006062A MX 2015006062 A MX2015006062 A MX 2015006062A MX 2015006062 A MX2015006062 A MX 2015006062A MX 2015006062 A MX2015006062 A MX 2015006062A
Authority
MX
Mexico
Prior art keywords
preparation
pyrimidine compounds
optionally substituted
sigma receptors
substituted pyrazolo
Prior art date
Application number
MX2015006062A
Other languages
English (en)
Inventor
Arjona Jordi Corbera
Carmen Almansa
José-Luis Díaz-Fernández
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2015006062A publication Critical patent/MX2015006062A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos pirazolo [3,4-d] pirimidina sustituidos de fórmula general (I) que tienen una gran afinidad por los receptores sigma, especialmente el receptor sigma-1, así como al proceso para su preparación, a composiciones que los comprenden y a su uso como medicamentos para el tratamiento de por ejemplo dolor. n se selecciona de entre 1, 2, 3 04; R1 representa un radical arilo o heteroarilo opcionalmente sustituido enlazado a carbono; R2 y R3 representan independientemente un átomo de hidrógeno, un alifático opcionalmente sustituido, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo o radical heterociclilalquilo, o R2 y R3 junto con el puente de nitrógeno forman un radical heterocicloalquilo opcionalmente sustituido o radical heteroarilo.
MX2015006062A 2012-11-14 2013-11-14 Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma. MX2015006062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382448.4A EP2733143A1 (en) 2012-11-14 2012-11-14 Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
PCT/EP2013/073801 WO2014076170A1 (en) 2012-11-14 2013-11-14 Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as|sigma receptors ligands

Publications (1)

Publication Number Publication Date
MX2015006062A true MX2015006062A (es) 2015-12-01

Family

ID=47278736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006062A MX2015006062A (es) 2012-11-14 2013-11-14 Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma.

Country Status (10)

Country Link
US (1) US9278974B2 (es)
EP (2) EP2733143A1 (es)
JP (1) JP6329961B2 (es)
CN (1) CN104903326B (es)
CA (1) CA2891629A1 (es)
ES (1) ES2608359T3 (es)
HK (1) HK1215248A1 (es)
MX (1) MX2015006062A (es)
PT (1) PT2920174T (es)
WO (1) WO2014076170A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones
CA3090746A1 (en) * 2018-02-16 2019-08-22 UCB Biopharma SRL Pharmaceutical 6,5 heterobicyclic ring derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
BR112023021381A2 (pt) * 2021-04-16 2023-12-19 Acondicionamiento Tarrasense Composto e seu processo de preparação, e composição farmacêutica
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1781619E (pt) * 2004-08-27 2011-11-04 Esteve Labor Dr Inibidores do recetor sigma
EP1634873A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
ES2539478T3 (es) * 2008-11-11 2015-07-01 Xcovery Holding Company Llc Inhibidores de PI3K/mTOR cinasa
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands

Also Published As

Publication number Publication date
EP2733143A1 (en) 2014-05-21
CN104903326A (zh) 2015-09-09
JP6329961B2 (ja) 2018-05-23
WO2014076170A1 (en) 2014-05-22
PT2920174T (pt) 2016-12-23
JP2015537018A (ja) 2015-12-24
US20150315192A1 (en) 2015-11-05
CA2891629A1 (en) 2014-05-22
EP2920174A1 (en) 2015-09-23
EP2920174B1 (en) 2016-09-21
CN104903326B (zh) 2017-11-17
ES2608359T3 (es) 2017-04-10
US9278974B2 (en) 2016-03-08
HK1215248A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
PH12016501822A1 (en) Cyclopropaneamine compound
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MD4664C9 (ro) Lactame aril şi heteroaril condensate
UA102088C2 (ru) Производные n-азабициклических карбоксамидов, их получение и применение в терапии
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
MX2012006994A (es) Agente antiplaquetas novedoso.
MY177250A (en) Novel nicotinamide derivative or salt thereof
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
MX355164B (es) Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MX2012012421A (es) Compuestos tetrahidrobenzotiofena.
MX2015006062A (es) Compuestos de pirazolo [3,4-d] pirimidina sustituidos, su preparacion y su uso como ligandos de sigma.
MX343893B (es) Nuevos derivados de aril-quinolina.
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12014502241A1 (en) Pharmaceutical formulations comprising ccr3 antagonists
PH12017501652A1 (en) Kv1.3 inhibitors and their medical application
MX2016002738A (es) Compuestos farmaceuticos.
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
MY183326A (en) New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them
MY170262A (en) Dicarboxylic acid compound
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MX2015006987A (es) Moduladores selectivos del receptor de androgenos novedosos.